Positive and Differentiated Results for Theraclion’s Non-invasive Varicose Vein Treatment Technology Revealed at The 34th A...
21 Octobre 2020 - 6:30PM
Business Wire
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE,
PEA-PME eligible), an innovative company specialized in echotherapy
treatment (using High Intensity Focused Ultrasound or HIFU),
announces highly positive results for its non-invasive echotherapy
solution, SONOVEIN.
Professor Dr. Mark Whiteley presented his results during the
34th annual congress of the American Vein & Lymphatic Society
(AVLS). AVLS is the premier and largest association for physicians
dedicated to treatment of venous disease. Prof. Mark Whiteley is a
renowned UK Venous Surgeon and Consultant Phlebologist, and founder
of The Whiteley Clinic.
Prof. Whiteley was the first to adopt SONOVEIN in
clinical routine. He presented his “6 months outcomes from High
Intensity Focused Ultrasound closure of incompetent saphenous and
perforator veins” at AVLS. Details on 6 months follow-up on 22
patients was presented.
- 94.5% of the patients suffered from varicose veins (C1 to C4
stages of the CEAP classification1)
- 45 veins were treated including Great Saphenous Veins, Small
Saphenous Veins, Anterior Accessory Saphenous Veins and Perforator
Veins
- 100% closure rate was achieved immediately after
SONOVEIN echotherapy on truncal veins
- Successful ablation of 82% after 2 months and 6 months of
perforator veins, which often do not have a satisfying treatment
option with current standards.
- the mean age was 55,5 years and the ratio male to female was
36% to 64%
“SONOVEIN, a high precision echotherapy solution,
represents the most progressive technology in the world for
treating varicose veins and venous leg ulcers. Unlike endovenous
laser, radiofrequency and even foam, this treatment is 100%
non-invasive. There is no other technique that is non-invasive and
can treat the vein from outside the body” explains Professor
Whiteley.
SONOVEIN S, Theraclion’s second generation technology,
was revealed just earlier this month.
SONOVEIN S – first patients already treated at the Whiteley
Clinics, London
Prof. Whiteley also presented his feedback on the second
generation technology of SONOVEIN during AVLS. “SONOVEIN
S is a game changer. It really does not need any form of
anaesthesia. This accelerates the treatment and identification of
the vein is very much easier than with existing methods.”
Chronic Venous Insufficiency (CVI) and venous ulceration
is a common health problem causing significant patient morbidity.
Apart from the chronic physical and psychological disability caused
to the individual, it also results in an enormous economic burden
to the health care administration. Global prevalence rates of CVI
are variable but may be as high as 40% among females and 17% among
males2. Venous pathology generates around 5 million treatment
procedures per year 3.
About Theraclion
Theraclion has developed an innovative high-tech echotherapy
solution using High Intensity Focused Ultrasound for the treatment
of varicose veins, SONOVEIN®. The treatment solution, which
obtained CE marking in April 2019, is based on the leading-edge
echotherapy treatment expertise developed over years by Theraclion
for non-invasive ablation of breast fibroadenomas and thyroid
nodules using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for a treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s offices or in clinics, as
well as in hospitals. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millennium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on high-tech
ultrasound medical imaging devices that are precise and easy to use
for practitioners.
Located in Malakoff, near Paris, Theraclion brings together a
team of 25 people, more than half of whom are dedicated to R&D
and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29
1
https://thewhiteleyclinic.co.uk/self-assessment/ceap-classification/
2 https://www.peertechz.com/articles/IJVSM-5-132.php 3 Millenium
research Varicose Vein Device Market Study 2015
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201021005797/en/
Theraclion
David Caumartin Chief Executive Officer Tél : + 33 (0)1 55 48 90
70 david.caumartin@theraclion.com
Anja Kleber VP Marketing, Market Access & Sales
Francophonia anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024